Literature DB >> 22315493

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.

Jeffrey J Pu1, Rong Hu, Galina L Mukhina, Hetty E Carraway, Michael A McDevitt, Robert A Brodsky.   

Abstract

BACKGROUND: Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation. Many patients with aplastic anemia and myelodysplastic syndromes also harbor small populations of glycosylphosphatidylinositol-anchor deficient cells. Patients with aplastic anemia often evolve into paroxysmal nocturnal hemoglobinuria; however, myelodysplastic syndromes seldom evolve into paroxysmal nocturnal hemoglobinuria. Here, we investigate the origin and clonality of small glycosylphosphatidylinositol-anchor deficient cell populations in aplastic anemia and myelodysplastic syndromes. DESIGN AND METHODS: We used peripheral blood flow cytometry to identify glycosylphosphatidylinositol-anchor deficient blood cells, a proaerolysin-resistant colony forming cell assay to select glycosylphosphatidylinositol-anchor deficient progenitor cells, a novel T-lymphocyte enrichment culture assay with proaerolysin selection to expand glycosylphosphatidylinositol-anchor deficient T lymphocytes, and PIG-A gene sequencing assays to identify and analyze PIG-A mutations in patients with aplastic anemia and myelodysplastic syndromes.
RESULTS: Twelve of 15 aplastic anemia patients were found to harbor a small population of glycosylphosphatidylinositol-anchor deficient granulocytes; 11 of them were found to harbor a small population of glycosylphosphatidylinositol-anchor deficient erythrocytes, 10 patients were detected to harbor glycosylphosphatidylinositol-anchor deficient T lymphocytes, and 3 of them were detected only after T-lymphocyte enrichment in proaerolysin selection. PIG-A mutation analyses on 3 patients showed that all of them harbored a matching PIG-A mutation between CFU-GM and enriched T lymphocytes. Two of 26 myelodysplastic syndromes were found to harbor small populations of glycosylphosphatidylinositol-anchor deficient granulocytes and erythrocytes transiently. Bone marrow derived CD34(+) cells from 4 patients grew proaerolysin-resistant colony forming cells bearing PIG-A mutations. No glycosylphosphatidylinositol-anchor deficient T lymphocytes were detected in myelodysplastic syndrome patients.
CONCLUSIONS: In contrast to aplastic anemia and paroxysmal nocturnal hemoglobinuria, where PIG-A mutations arise from multipotent hematopoietic stem cells, glycosylphosphatidylinositol-anchor deficient cells in myelodysplastic syndromes appear to arise from more committed progenitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315493      PMCID: PMC3409821          DOI: 10.3324/haematol.2011.048215

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  37 in total

1.  Selection of patients for bone marrow transplantation in severe aplastic anemia.

Authors:  B M Camitta; J M Rappeport; R Parkman; D G Nathan
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

Review 2.  The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated.

Authors:  N S Young
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

3.  Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia.

Authors:  Jeffrey J Pu; Galina Mukhina; Hao Wang; William J Savage; Robert A Brodsky
Journal:  Eur J Haematol       Date:  2011-07       Impact factor: 2.997

4.  Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome.

Authors:  J P Maciejewski; D Follmann; R Nakamura; Y Saunthararajah; C E Rivera; T Simonis; K E Brown; J A Barrett; N S Young
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin.

Authors:  R A Brodsky; G L Mukhina; S Li; K L Nelson; P L Chiurazzi; J T Buckley; M J Borowitz
Journal:  Am J Clin Pathol       Date:  2000-09       Impact factor: 2.493

6.  Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party.

Authors:  A Bacigalupo; J Hows; E Gluckman; C Nissen; J Marsh; M T Van Lint; M Congiu; M M De Planque; P Ernst; S McCann
Journal:  Br J Haematol       Date:  1988-10       Impact factor: 6.998

7.  Limited heterogeneity of T cell receptor BV usage in aplastic anemia.

Authors:  W Zeng; J P Maciejewski; G Chen; N S Young
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia.

Authors:  G L Mukhina; J T Buckley; J P Barber; R J Jones; R A Brodsky
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

9.  Late clonal complications in severe aplastic anemia.

Authors:  A Tichelli; A Gratwohl; C Nissen; B Speck
Journal:  Leuk Lymphoma       Date:  1994-01

10.  Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.

Authors:  M Bessler; P J Mason; P Hillmen; T Miyata; N Yamada; J Takeda; L Luzzatto; T Kinoshita
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

View more
  9 in total

1.  Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

Authors:  S A Wong; B I Dalal; H A Leitch
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 2.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 3.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

Review 4.  Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.

Authors:  Aaron T Gerds; Bart L Scott
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 5.  The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

Authors:  Amy E DeZern; Mikkael A Sekeres
Journal:  Oncologist       Date:  2014-06-04

6.  Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders.

Authors:  Amy E DeZern; Jeffrey Pu; Michael A McDevitt; Richard J Jones; Robert A Brodsky
Journal:  Exp Hematol       Date:  2013-05-06       Impact factor: 3.084

7.  PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Authors:  Emmanuel K Teye; Abigail Sido; Ping Xin; Niklas K Finnberg; Prashanth Gokare; Yuka I Kawasawa; Anna C Salzberg; Sara Shimko; Michael Bayerl; W Christopher Ehmann; David F Claxton; Witold B Rybka; Joseph J Drabick; Hong-Gang Wang; Thomas Abraham; Wafik S El-Deiry; Robert A Brodsky; Raymond J Hohl; Jeffrey J Pu
Journal:  Oncotarget       Date:  2017-05-02

8.  Independent Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Syndrome Clones in a Patient With Complete Bone Marrow Failure.

Authors:  Masayuki Mita; Tsutomu Shichishima; Hideyoshi Noji; Hiroshi Takahashi; Ken-Ichi Nakamura; Takayuki Ikezoe
Journal:  Hemasphere       Date:  2018-10-02

9.  The spectrum of paroxysmal nocturnal hemoglobinuria clinical presentation in a Brazilian single referral center.

Authors:  Bruno G P Pires da Silva; Natasha P Fonseca; Luis Fernando B Catto; Gabriel C Pereira; Rodrigo T Calado
Journal:  Ann Hematol       Date:  2022-02-18       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.